Our CEO, Gurutz Linazasoro, interviewed by Diario Vasco

Our CEO was interviewed by Diario Vasco and confirmed that VIVEbiotech is immersed in a capital increase to multiply its capacity tenfold and meet much greater market demands.

In addition to manufacturing standard lentiviruses, VIVEbiotech develops proprietary vectors with its patented technology called LENTISOMA.

As Dr Linazasoro indicated, VIVEbiotech works in the medicine of the future, which will offer the 5 P-s: preventive, participative, precise, personalized and predictive.

The interview was published yesterday, March 18, and can be read here.

Contact us

Mikeletegi Pasealekua 81, San Sebastián 20009, Gipuzkoa (SPAIN)